human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)
This federal contract opportunity has been awarded to on May 29, 2025.
Award Information
This solicitation resulted in an award to for approximately $2,000,000 on May 29, 2025. Similar contracts are typically issued by DEPT OF DEFENSE under 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
- Award Number
- HT9425-25-D-0009
- Award Amount
- $2,000,000
- Award Date
- May 29, 2025
Key Takeaways
- No response deadline specified - contact the agency for details
- Full and open competition - all businesses eligible to bid
- Work to be performed in FORT DETRICK, MD
- Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Contract Details
- Notice ID
- HT9425-25-D-0009
- Opportunity Type
- Award Notice
- Agency
- DEPT OF DEFENSE
- Sub-Agency
- DEFENSE HEALTH AGENCY (DHA)
- Office
- ARMY MED RES ACQ ACTIVITY
- Posted Date
- Wednesday, June 4, 2025
- Response Deadline
- Not specified
- PSC Code
- 6550
- Set-Aside
- Full & Open Competition
- Place of Performance
- FORT DETRICK, MD, 21702
- Status
- Active
Description
Mapp Biopharmaceutical, Inc. received a Firm Fix Price Sole Source IDIQ award for the delivery of human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags) in support of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
Why This Opportunity Matters
The Department of DEFENSE is seeking responses for research and development in biotechnology (except nanobiotechnology) in FORT DETRICK, MD.
Similar Opportunities
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
